Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry by Lauten, Alexander et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Percutaneous left-ventricular support with the Impella-2.5-assist device in
acute cardiogenic shock: results of the Impella-EUROSHOCK-registry
Lauten, Alexander; Engström, Annemarie E; Jung, Christian; Empen, Klaus; Erne, Paul; Cook,
Stéphane; Windecker, Stephan; Bergmann, Martin W; Klingenberg, Roland; Lüscher, Thomas F;
Haude, Michael; Rulands, Dierk; Butter, Christian; Ullman, Bengt; Hellgren, Laila; Modena, Maria
Grazia; Pedrazzini, Giovanni; Henriques, Jose P S; Figulla, Hans R; Ferrari, Markus
Abstract: Background- Acute cardiogenic shock after myocardial infarction is associated with high in-
hospital mortality attributable to persisting low-cardiac output. The Impella-EUROSHOCK-registry
evaluates the safety and efficacy of the Impella-2.5-percutaneous left-ventricular assist device in patients
with cardiogenic shock after acute myocardial infarction. Methods and Results- This multicenter reg-
istry retrospectively included 120 patients (63.6±12.2 years; 81.7% male) with cardiogenic shock from
acute myocardial infarction receiving temporary circulatory support with the Impella-2.5-percutaneous
left-ventricular assist device. The primary end point evaluated mortality at 30 days. The secondary end
point analyzed the change of plasma lactate after the institution of hemodynamic support, and the rate of
early major adverse cardiac and cerebrovascular events as well as long-term survival. Thirty-day mortality
was 64.2% in the study population. After Impella-2.5-percutaneous left-ventricular assist device implan-
tation, lactate levels decreased from 5.8±5.0 mmol/L to 4.7±5.4 mmol/L (P=0.28) and 2.5±2.6 mmol/L
(P=0.023) at 24 and 48 hours, respectively. Early major adverse cardiac and cerebrovascular events were
reported in 18 (15%) patients. Major bleeding at the vascular access site, hemolysis, and pericardial
tamponade occurred in 34 (28.6%), 9 (7.5%), and 2 (1.7%) patients, respectively. The parameters of age
>65 and lactate level >3.8 mmol/L at admission were identified as predictors of 30-day mortality. After
317±526 days of follow-up, survival was 28.3%. Conclusions- In patients with acute cardiogenic shock
from acute myocardial infarction, Impella 2.5-treatment is feasible and results in a reduction of lactate
levels, suggesting improved organ perfusion. However, 30-day mortality remains high in these patients.
This likely reflects the last-resort character of Impella-2.5-application in selected patients with a poor
hemodynamic profile and a greater imminent risk of death. Carefully conducted randomized controlled
trials are necessary to evaluate the efficacy of Impella-2.5-support in this high-risk patient group.
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Historically, cardiogenic shock (CS) attributable to acute myocardial infarction (AMI) has been associated with 
in-hospital mortality rates as high as 80%.1 Even in the era of 
prompt revascularization, mortality rates for CS remain high, 
and many patients with severe and profound CS succumb to 
multiple organ failure secondary to persistent inadequate end-
organ perfusion.2–7 In addition to early revascularization and 
pharmacological therapy, mechanical support by means of 
intra-aortic balloon counterpulsation (IABP) is recommended 
(class I) by the current guidelines.8,9 However, as the IABP 
augments native cardiac function, this treatment provides 
only limited hemodynamic support in patients with severely 
depressed myocardial function or cardiac arrest. Thus, several 
clinical trials as well as a recent meta-analysis have failed to 
demonstrate the benefit of IABP therapy on left-ventricular 
(LV) function or survival.10–13
Clinical Perspective on p 30
New percutaneous LV assist devices (pLVAD) have been 
developed for mechanical circulatory support, including 
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Background—Acute cardiogenic shock after myocardial infarction is associated with high in-hospital mortality attributable 
to persisting low-cardiac output. The Impella–EUROSHOCK-registry evaluates the safety and efficacy of the Impella-
2.5–percutaneous left-ventricular assist device in patients with cardiogenic shock after acute myocardial infarction.
Methods and Results—This multicenter registry retrospectively included 120 patients (63.6±12.2 years; 81.7% male) with 
cardiogenic shock from acute myocardial infarction receiving temporary circulatory support with the Impella-2.5–percutaneous 
left-ventricular assist device. The primary end point evaluated mortality at 30 days. The secondary end point analyzed the change 
of plasma lactate after the institution of hemodynamic support, and the rate of early major adverse cardiac and cerebrovascular 
events as well as long-term survival. Thirty-day mortality was 64.2% in the study population. After Impella-2.5–percutaneous 
left-ventricular assist device implantation, lactate levels decreased from 5.8±5.0 mmol/L to 4.7±5.4 mmol/L (P=0.28) and 
2.5±2.6 mmol/L (P=0.023) at 24 and 48 hours, respectively. Early major adverse cardiac and cerebrovascular events were 
reported in 18 (15%) patients. Major bleeding at the vascular access site, hemolysis, and pericardial tamponade occurred in 34 
(28.6%), 9 (7.5%), and 2 (1.7%) patients, respectively. The parameters of age >65 and lactate level >3.8 mmol/L at admission 
were identified as predictors of 30-day mortality. After 317±526 days of follow-up, survival was 28.3%.
Conclusions—In patients with acute cardiogenic shock from acute myocardial infarction, Impella 2.5–treatment is feasible 
and results in a reduction of lactate levels, suggesting improved organ perfusion. However, 30-day mortality remains 
high in these patients. This likely reflects the last-resort character of Impella-2.5–application in selected patients with a 
poor hemodynamic profile and a greater imminent risk of death. Carefully conducted randomized controlled trials are 
necessary to evaluate the efficacy of Impella-2.5–support in this high-risk patient group. (Circ Heart Fail. 2013;6:23-30.)
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the Impella-2.5–system (Abiomed Europe GmbH, Aachen, 
Germany). These devices unload the left ventricle and par-
tially replace myocardial function, thus, potentially promoting 
myocardial recovery. The Impella-2.5 is a catheter-mounted 
axial-flow pump, which can be inserted percutaneously, and 
provides a maximum flow of 2.5 L/min. Short-term circula-
tory support with the device has been demonstrated to be safe 
and feasible in high-risk percutaneous coronary intervention 
(PCI) as well as in the setting of hemodynamically stable large 
anterior ST-elevation myocardial infarction.14–17 In patients 
with CS, a small randomized clinical trial of Impella-2.5 
versus IABP demonstrated an improvement in cardiac index 
in Impella-treated patients.18 The purpose of the multicenter 
Impella–EUROSHOCK-registry was to assess procedural 
safety and outcome of Impella-2.5–support in a large cohort 
of patients with acute CS.
Methods
Study Design and Collection of Data
A total of 14 tertiary cardiovascular centers located in 5 countries 
across Europe contributed data to the Impella–EUROSHOCK-
registry. Data were collected at each site using a standardized case 
report form to record demographic and clinical characteristics, as 
well as procedural and follow-up data. Follow-up was obtained at 30 
days and at the time of registry enrollment based on medical records 
and on physician or patient interviews. The study was approved by 
the Institutional Review Board of the University Heart Center Jena 
and supported by Abiomed Europe GmbH (Aachen, Germany) for 
the identification of sites of enrollment. The investigators had full 
access to the data and control of the data analysis.
Inclusion Criteria and Treatment
At each site, all patients receiving emergent Impella-2.5–support 
during a 5-year period (2005–2010) for acute CS after AMI were 
included. The diagnosis of AMI was based on the results of coronary 
angiography and on laboratory and electrocardiographic studies. CS 
was a clinical diagnosis based on the definition from the SHOCK 
(Should We Emergently Revascularize Occluded Coronaries for 
Cardiogenic Shock) trial, including (1) the presence of a systolic 
blood pressure≤90 mm Hg for at least 30 minutes or (2) vasopressors 
required to maintain blood pressure >90 mm Hg, (3) evidence of end-
organ hypoperfusion (eg, urine output <30 mL or cold, diaphoretic 
extremities, or altered mental status), and (4) evidence of elevated 
filling pressures (eg, pulmonary congestion on examination or chest 
radiograph).19 In each patient, therapy was tailored to the rapidly 
changing hemodynamic status and included mechanical ventilation, 
fluid administration, pharmacological treatment (inotropes, vasopres-
sors) and IABP-support if considered necessary. The amount of fluid 
administration as well as the choice of inotropes and vasopressors 
was based on current guidelines and on individual experience and 
institutional policy. Doses were titrated to achieve a systolic blood 
pressure of at least 80 mm Hg.20,21 The decision to institute circulatory 
support with the Impella-2.5 was made in patients with refractory CS 
unresponsive to high-dose inotropes and IABP-support at the time of 
primary PCI.
After hemodynamic improvement, weaning from circulatory sup-
port was considered in the absence of hemodynamic or clinical signs 
of CS. Weaning criteria included a mean arterial pressure >70 mm Hg 
and a cardiac index >2.2 L/min/m2 without a requirement of inotro-
pic support and evidence of end-organ hypoperfusion. Weaning was 
performed by decreasing the pump performance level in 2 steps in 
intervals of 30 to 60 minutes. After reduction to performance level 
P2 (range, P1–P9; P9=maximum flow) for 10 minutes without hemo-
dynamic instability, the Impella pump was pulled back into the aorta 
and explanted.
Device
The Impella-2.5–device has been described previously.15 In brief, it is 
a catheter-mounted microaxial rotary blood pump designed for rapid 
percutaneous insertion under fluoroscopy to allow for temporary LV 
support. The device is inserted through a 13F femoral sheath and 
positioned retrogradely across the aortic valve in the LV. Equipped 
with a pigtail-tip to avoid myocardial injury and to ensure a stable 
position in the LV, the Impella-2.5 provides a maximum flow of 2.5 
L/min by expelling blood from the LV into the ascending aorta. The 
degree of support can be managed by graduation of pump speed up 
to a maximal rotation speed of 51.000 rpm. The device has received 
CE-approval in Europe for 5-day use.
Study End Points
The primary end point of the study was all-cause mortality at 30 days. 
The secondary end points were long-term survival and parameters of 
device efficacy and safety. The secondary efficacy end point evalu-
ated the change in level of plasma lactate within 24 and 48 hours 
after the beginning of Impella-2.5–support. Secondary end points 
also included procedural feasibility, the incidence of major cardiac 
and cerebral events (recurrent myocardial infarction or cardiovascu-
lar interventions [PCI, coronary artery bypass grafting] and stroke), 
device-related vascular complications (bleeding requiring transfusion 
or surgery), hemolysis, cardiac tamponade, and device malfunction.
Statistics
Continuous data are presented as mean±SD, categorical variables are 
presented as percentages and numbers. All variables were tested for 
normal distribution with the Shapiro-Wilk–test. Univariate logistic 
regression was performed among established predictors of 30-day 
mortality. Age was dichotomized to above and below the median of 
65 years. Systolic blood pressure was dichotomized to above and 
below the median of 90 mm Hg. Lactate at baseline was dichoto-
mized to above and below the median of 3.8 mmol/L. All covari-
ates with a P<0.1 were included in the multivariate regression model. 
Backward stepwise logistic regression analysis was subsequently 
performed, to identify independent predictors for 30-day mortality. A 
covariate was removed from the model if the P value exceeded 0.10. 
All P<0.05 were considered statistically significant. Kaplan–Meier 
curves were constructed and stratified according to lactate levels 
above and below the median. Survival differences were tested using 
the log-rank statistic. All statistical analyses were performed with the 
Statistical Package for the Social Sciences (SPSS Inc, Chicago, IL, 
version 18.0).
Results
Patient Characteristics at Hospital Admission
The Impella–EUROSHOCK-registry included a total of 120 
patients with AMI and CS treated with the Impella-2.5 in 14 
European cardiovascular centers. Baseline characteristics are 
detailed in Table 1. Mean age was 63.6±12.3 years, 98 (81.7%) 
patients were male. In accordance with the inclusion criteria, 
all patients were in profound CS with a low mean arterial 
blood pressure (68.3±17.3 mm Hg), an elevated plasma 
lactate (5.8±5.0 mmol/L) and a severely reduced LV ejection 
fraction (0.27±0.11; determined by either echocardiography 
or ventriculography). At the time of device implantation, 102 
(85%) patients received vasopressors and inotropics, and 35 
(29.0%) were on IABP-support. In addition, 40.8% (n=49) of 
the patients had been resuscitated for out-of-hospital cardiac 
arrest. The majority of patients (n=81, 67.5%) presented with 
multivessel disease with a severely reduced mean thrombolysis 
in myocardial infarction flow at the culprit lesion of 0.4±0.8, 
which improved after PCI to 2.6±0.9.
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Thirty-Day Mortality
Thirty-day mortality in this study cohort was 64.2% (77/120 
patients). Multivariate logistic regression analysis was 
performed to identify independent parameters for 30-day 
mortality (Table 2). After stepwise backward analysis, the 
parameters age>65 (odds ratios, 5.46; P=0.008) and blood 
lactate >3.8 mmol/L (P=0.012) remained in the model as 
independent predictors for 30-day mortality with odds ratios 
of 5.245 (95% confidence interval, 1.473–18.677; P=0.011) 
and 5.245 (95% confidence interval, 1.473–18.677; P=0.011) 
respectively (Table 3).
Clinical Course
The mean duration of Impella-2.5–support was 43.5±49.6 
hours in the overall study cohort. Fifty patients (42%) died 
during Impella-2.5–support. Within the overall study group, 
53 (44.5%) patients were successfully weaned from the 
device after a mean support duration of 66.3±54 hours. Within 
the subgroup of successfully weaned patients, 18/53 (34%) 
patients had died after further treatment at 30 days. In 6 
patients (5.0%), circulatory support with the Impella-2.5 was 
discontinued because of associated complications (vascular:5; 
hemolysis:1).
After device implantation, mean plasma lactate levels 
decreased from 5.8±5.0 mmol/L to 4.7±5.4 mmol/L (P=0.28) 
at 24 hours and to 2.5±2.6 mmol/L (P=0.023) at 48 hours of 
device support. In patients presenting with a lactate above 
the median of 3.8 mmol/L, plasma lactate decreased from 
9.3±4.9 mmol/L to 6.4±6.3 mmol/L (P=0.06) after 24 hours 
and to 4.0±4.0 mmol/L (P=0.007) after 48 hours. Further 
details on laboratory measurements are presented in Table 2. 
Survival after a mean follow-up of 317±526 days was 28.3%. 
The Kaplan–Meier Curves for the overall-group, as well as 
Kaplan–Meier curves stratified by plasma lactate at admission 
and with or without cardiopulmonary resuscitation <72 hours, 
are provided in Figures 1 and 2.
In the overall study population, 10 patients (8.4%) required 
upgrading to other circulatory assist devices with a higher 
maximum pump flow (Impella-5.0: n=6; extracorporeal mem-
brane oxygenation: n=2; surgical LVAD: n=2). Decisions for 
upgrade were influenced by clinical judgment and the per-
sistence of severe hypotension or suboptimal cardiac output 
despite Impella-2.5 and inotropic support. The 30-day mortal-
ity in the subgroup of patients upgraded to other devices was 
60% (n=6).
Table 1. Baseline Characteristics (n=120)
Baseline
(N=120)
Age, years±SD 63.6±12.2
Male, n (%) 98 (81.7)
Cardiac risk factors
 Body mass index >25 kg/m2, n (%) 75 (57.3)
 Hypertension, n (%) 66 (55.0)
 Diabetes mellitus, n (%) 37 (30.8)
 Current smoker, n (%) 33 (27.5)
 Hypercholesterolemia, n (%) 41 (34.2)
Previous medical history
 Chronic obstructive pulmonary disease, n (%) 13 (10.8)
 Renal insufficiency, n (%) 27 (22.5)
 Atrial fibrillation, n (%) 25 (19.1)
 Stroke, n (%) 2 (1.7)
 Peripheral vascular disease, n (%) 13 (10.8)
 Previous myocardial infarction, n (%) 35 (29.2)
 Myocardial infarction within 90 d, n (%) 17 (14.2)
 Previous coronary artery bypass grafting, n (%) 7 (5.8)
Additional treatment on admission
 Inotropes and vasopressors, n (%) 102 (85.0)
 Mechanical ventilation, n (%) 83 (69.2)
 Intra-aortic counterpulsation, n (%) 35 (29.2)
 Primary PCI, n (%) 101 (93.2)
 CPR within 72 h before device implantation 49 (40.8)
Hemodynamics and laboratory measurements
 Systolic blood pressure, mm Hg±SD 90.2±22.3
 Diastolic blood pressure, mm Hg±SD 56.6±17.3
 Mean blood pressure, mm Hg±SD 68.1±17.9
 Heart rate, bpm±SD 100±23
 Ejection fraction±SD 0.27±0.12
 Lactate, mmol/L±SD 5.8±4.9
Coronary status
 Multivessel disease, n (%) 81 (67.5)
 Number of lesions treated 1.7±1.2
 TIMI-flow before intervention 0.4±0.8
 TIMI-flow after intervention 2.6±0.9
Values as mean±SD or n (%). Bpm indicates beats per minute; CPR, car-
diopulmonary resuscitation; PCI, percutaneous coronary intervention; and TIMI, 
thrombolysis in myocardial infarction.
Table 2. Mortality at 30 Days and Secondary Efficacy End 
Points
Baseline
(N=120)
Primary end point
 Mortality at 30 d 77 (64.2)
 Death on circulatory support 50 (42.0)
 Successfully weaned from support 53 (44.5)
 Long-term survival (after 317±526 d) 34 (28.3)
Secondary end points
 Successful implantation procedure 119 (99.2)
 Procedure rated easy or suitable 114 (95%)
 Duration of Impella-2.5–support, hours 43.5±49.6
 Efficacy
Overall 
group
Subgroup with initial 
lactate >3.8 mmol/L
 Plasma lactate at admission, mmol/L 5.8±5.0 9.3±4.9
 Plasma lactate after 24 h, mmol/L 4.7±5.4 6.4±6.3
 Plasma lactate after 48 h, mmol/L 2.5±2.6* 4.0±4.0†
Values as n (%) or mean±SD.
*P=0.023 compared with baseline; †P=0.007 compared with baseline.
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Patients requiring cardiopulmonary resuscitation within 
72 hours before Impella-2.5–implantation had a significantly 
lower survival at 30 days compared with patients not requir-
ing cardiopulmonary resuscitation (24.5% versus 43.7%; 
P=0.002; Figure 2B). However, the requirement of cardiopul-
monary resuscitation before institution of hemodynamic sup-
port was no independent predictor of early mortality in the 
multivariate logistic regression analysis (Table 3).
Feasibility and Safety
The Impella-2.5 was successfully implanted in 119 (99.2%) 
patients. The implantation procedure was considered easy or 
suitable by the implanting physician in 114 (95%) patients. In 
1 patient (0.8%), transfemoral placement of the Impella-2.5 
failed and intra-aortic counterpulsation was used subsequently. 
In patients successfully weaned or upgraded to other devices, 
the explantation procedure was rated easy or suitable in 66 
(95.7%) patients.
Major adverse cardiac and cerebrovascular events in the 
overall study group were reported in 18 (15%) cases (myo-
cardial infarction: n=8; Re-PCI: n=13; coronary artery bypass 
grafting: n=3; stroke: n=2). Complications associated with 
Impella-2.5–support included bleeding at the vascular access 
site requiring transfusion in 29 (24.2%) and vascular surgery 
in 5 (4.2%) patients. Hemolysis resulting in blood transfu-
sion was reported in 9 (7.5%) cases. In 2 (1.7%) patients, 
pericardial drainage was necessary because of hemodynami-
cally relevant pericardial tamponade after the Impella place-
ment. Device malfunction necessitating explantation occurred 
in 3 (2.5%) patients during long-term support. Details on 
safety end points are presented in Table 4.
Discussion
Mechanical Support for CS
In current practice, CS complicates 5% to 15% of cases with 
AMI and is still associated with high in-hospital mortality 
rates.1,5,7,22 Intra-aortic counterpulsation is considered the first 
line of treatment for patients requiring mechanical support and 
is recommended with a class I recommendation according to 
American Heart Association/American College of Cardiology 
and European Society of Cardiology guidelines.8,23 Contem-
porary IABP usage ranges from 11% to 86% in patients with 
CS.1,11,19,24,25 However, so far there is no data from randomized 
controlled trials demonstrating a survival benefit of IABP-
therapy, and its efficacy has recently been questioned.10,26,27
Ventricular assist devices are a promising alternative for 
patients with CS as they provide hemodynamic support 
by replacing LV function and, thus, may allow for recov-
ery of hibernating or stunned myocardium. However, surgi-
cal LVADs frequently require time-consuming and complex 
implantation procedures. They are themselves associated 
Table 3. Regression Analysis of Predictors of 30-Day Mortality (n=120)
Univariate
Variable OR (95% CI) P
Age >65 2.085 (0.969–4.484) 0.06
Male sex 1.641 (0.642–4.193) 0.30
Diabetes mellitus 1.045 (0.465–2.349) 0.92
COPD 0.881 (0.269–2.883) 0.83
Renal insufficiency 0.421 (0.176–1.007) 0.052
Stroke 0.553 (0.034–9.063) 0.68
Previous MI 0.394 (0.175–0.885) 0.024
Mechanical ventilation 1.339 (0.603–2.976) 0.473
CPR 2.390 (1.071–5.331) 0.033
IABP 2.362 (0.961–5.808) 0.061
Systolic BP <90 mm Hg 2.250 (1.018–4.972) 0.045
Lactate >3.8 mmol 3.750 (1.225–11.481) 0.021
Multivariate
First Step Final Model
Variable OR (95% CI) P OR (95% CI) P
Age >65 6.658 (1.616–27.432) 0.009 5.245 (1.473–18.677) 0.011
Renal insufficiency 0.733 (0.148–3.628) 0.703
Previous MI 0.412 (0.107–1.588) 0.198
CPR 1.899 (0.451–8.007) 0.382
IABP 2.209 (0.475–10.27) 0.312
Systolic BP <90 mm Hg 1.523 (0.372–6.228) 0.558
Lactate >3.8 mmol 4.986 (1.24–20.053) 0.024 5.245 (1.473–18.677) 0.011
Logistic regression analysis of predictors of 30-d mortality. BP indicates blood pressure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPR, 
cardiopulmonary resuscitation; IABP, intra-aortic balloon counterpulsation; MI, myocardial infarction; and OR, odds ratio.
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with a significant morbidity and mortality and their invasive-
ness precludes urgent implantation on presentation in patients 
with acute CS.28–30 Therefore, percutaneous devices have been 
developed, including the Impella-2.5–system.
Current Evidence for Hemodynamic Support With 
the Impella-2.5 in Acute CS
In contrast to other percutaneous devices, the Impella-2.5 is a 
less invasive system that allows for rapid transcatheter introduc-
tion using standard catheterization techniques and that provides 
a maximal pump flow of 2.5 L/min. A larger version of the 
Impella system is available as well, which is capable of provid-
ing a maximum flow of 5.0 L/min. However, this device requires 
a surgical cut-down of the femoral artery. The Impella-2.5 has 
been demonstrated to be safe and feasible in elective use during 
high-risk PCI as well as in patients with ST-elevation myocar-
dial infarction without CS.14–17 It has been demonstrated to pro-
mote myocardial recovery by LV unloading and to result in an 
immediate reduction of diastolic LV wall stress and pulmonary 
capillary wedge pressure.17,18,31 Furthermore, beneficial effects 
of the system on cerebral perfusion during cardiac arrest have 
been reported in the experimental setting.32
However, clinical data on efficacy of the Impella-2.5 in 
patients with CS is still limited. In a small series in 6 patients 
with CS after ST-elevation myocardial infarction, circula-
tory support with the Impella system resulted in hemody-
namic improvement with a decrease of blood lactate levels.33 
In the small randomized ISAR-Shock (Efficacy Study of LV 
Assist Device to Treat Patients With Cardiogenic Shock) trial 
comparing hemodynamic support with the Impella-2.5 and 
IABP (Impella: n=12; IABP: n=13), the device resulted in an 
improved cardiac index, but failed to improve survival.18
The present report based on data from the Impella–
EUROSHOCK-registry is the largest series to date investi-
gating emergency support with the Impella-2.5–device for 
treatment-refractory CS. Although survival rates in patients 
with CS vary among the current literature, 30-day survival in 
the present study was 35.8% and seems rather low.6,18,34,35 The 
excess mortality is likely the result of a selection bias favoring 
critically ill patients with a particularly poor hemodynamic 
profile and a greater imminent risk of death. Although rather 
disappointing, this data reflect the outcome in a subgroup of 
patients who have failed to improve with first-line treatment 
and in whom the pLVAD is frequently used as last-resort 
Figure 1. Overall long-term survival: Kaplan–Meier curve of 120  
patients showing survival after 317±526 days (survival rate 28.3%).
Figure 2. A, Kaplan–Meier survival curves stratified by plasma 
lactate levels below and above median (3.8 mmol/L) at admission 
demonstrate a lower 30-day survival in patients with lactate ≥3.8 
mmol/L compared with patients with a lactate <3.8 mmol/  
(18.2 vs 46%; P<0.001). B, Thirty-day survival in patients requir-
ing cardiopulmonary resuscitation (CPR) <72 hours before 
Impella-2.5–implantation is significantly lower compared with 
patients without CPR (24.5% vs 43.7%; P=0.002).
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option. This observation is also in line with the results of 
a recent study by Engström et al36 reporting an even lower 
30-day survival rate of 24% in a series of 34 patients with CS 
after ST-elevation myocardial infarction.
Indeed, compared with the ISAR–Shock trial, patients 
enrolled in the Impella–EUROSHOCK-registry had a poorer 
hemodynamic profile at the time of device implantation with 
a lower systolic and diastolic blood pressure (106±22 and 
64±15 mm Hg versus 91±21 and 57±17 mm Hg).18 Compared 
with other reports, a larger proportion of the study population 
had been resuscitated for cardiac arrest, and plasma lactate 
levels were higher (4.7±2.6 versus 5.97±5.0) at admission, 
thus, reflecting refractory CS with severe organ hypoperfu-
sion at this time.37
The observations made in the Impella–EUROSHOCK-
registry confirm that use of the Impella-2.5 is feasible in the 
emergency setting and represents a rapid method of instituting 
hemodynamic support, also in less-experienced centers. The 
device was easy to implant with a high procedural success rate 
and performed well. Despite the prolonged duration of support 
(43.5, range 0–210 hours), the rate of device-associated com-
plications was acceptable in this study population, although 
higher than reported from nonemergent pLVAD-application.14 
Bleeding complications requiring transfusion occurred in 
24.2% (n=29) patients, whereas surgical treatment of bleed-
ing complications was required in 5 (4.2%) patients (Table 
4). Although Seyfarth et al18 did not observe any vascular or 
bleeding complications in the ISAR–Shock-trial, this was a 
relatively small trial performed in a highly experienced cen-
ter. Importantly, complication rate of Impella-2.5–treatment is 
low when compared with the TandemHeart pLVAD.35,37
Clinical Implications
The Impella–EUROSHOCK-registry reflects the real-world 
use of the Impella-2.5 in contemporary practice outside of ran-
domized trials. Based on these data, this potentially effective 
therapy is currently rather restricted to patients with refractory 
CS who have failed to improve with first-line treatment. This 
is attributable to the current lack of data demonstrating a clini-
cal benefit with these devices as well as the current guidelines 
recommending intra-aortic counterpulsation as first-line for 
patients requiring mechanical support.38,39 Another issue is the 
higher cost of pLVADs when compared with IABP-therapy.25
The present study demonstrates the feasibility and ease of 
Impella-2.5–implantation in patients requiring urgent hemo-
dynamic support even in less-experienced centers. Also not 
based on randomized trials, this type of hemodynamic support 
should be considered early in patients failing to improve with 
first-line therapy. Furthermore, plasma lactate at the time of 
implantation has a prognostic impact and may also be used 
as metabolic marker of hypoperfusion, aiding in guiding ther-
apy. A significant decrease in plasma lactate after the begin-
ning of Impella treatment suggests at least partial reversal of 
hypoperfusion and supports the hemodynamic efficacy of the 
device. These findings are in line with data reported in the 
literature.39 Possibly, patients with lactate levels on admission 
above 3.8 mmol/L, as well as patients who continue to have 
high plasma lactate levels on Impella-2.5–support, should be 
considered for upgrading to more powerful assist devices (eg, 
the Impella 5.0), although this recommended strategy is rather 
based on experience than actual data.36 The present analysis 
failed to demonstrate a survival benefit for patients upgraded 
to other devices. This may be attributable to the small number 
of patients as well as confounding factors, such as the time 
delay associated with the decision to upgrade.
Study Limitations
This study represents by far the largest real-world cohort of 
patients treated with the Impella-2.5 in CS to date. However, 
several limitations should be acknowledged with regard to the 
current report. First, the lack of a control group as typical for a 
registry hampers definite conclusions on efficacy of Impella-
2.5–support. Second, because of the retrospective nature of 
data collection, detailed hemodynamic data after Impella 
implantation, in particular cardiac output, are not available. In 
emergency situations, in patients requiring circulatory support, 
an extensive hemodynamic evaluation is often not possible 
and not performed outside of randomized trials. The availabil-
ity of data was limited to standard parameters recorded dur-
ing clinical routine in all participating centers. However, this 
might be of minor significance as the hemodynamic benefit of 
LVAD-support is well documented and similar effects may be 
assumed in the Impella–EUROSHOCK population.18 Third, 
selection bias may have influenced the outcome, as treatment 
with the Impella-2.5 has preferentially been given to the most 
severely ill patients. Finally, patients were included retrospec-
tively during a period of 5 years also covering the learning 
curve of the participating center in use of the Impella-2.5. This 
may impact selection of patients as well as the time point of 
device implantation in the individual centers.
In conclusion, the use of the Impella-2.5 for hemodynamic 
support in refractory CS is feasible although associated with 
a high complication rate. The high 30-day mortality rate may 
reflect the selection of patients with major hemodynamic 
compromise and high risk of imminent death. In a severely 
ill patient population with lactic acidosis, this device may not 
Table 4. Secondary Safety End Points
Baseline
(N=120)
MACCE (total) 18 (15.0)
 Myocardial infarction 8 (6.7)
 Re-PCI 13 (10.8)
 CABG 3 (2.5)
 Stroke 2 (1.7)
Bleeding requiring transfusion 29 (24.2)
Bleeding requiring surgery 5 (4.2)
Hemolysis 9 (7.5)
Pericardial drainage 2 (1.7)
Device malfunction 3 (2.5)
Renal failure 38 (31.7)
Renal failure requiring dialysis 28 (23.8)
Multiple organ failure 37 (30.8)
Values as n (%) or mean±SD. CABG indicates coronary artery bypass graft-
ing; MACCE, major adverse cardiac and cerebrovascular events; and PCI, per-
cutaneous coronary intervention.
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provide adequate ventricular unloading or systemic perfusion. 
Particularly in patients with profound CS, the Impella-2.5 may 
need to be upgraded early to more powerful devices. Further 
studies and adequately powered clinical trials are necessary 
to improve selection and timing for device support for this 
indication.
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The Impella–EUROSHOCK-registry is the largest real-world cohort of patients treated with the Impella-2.5 in cardiogenic 
shock to date—thus, reflecting the real-world use of the device in contemporary practice. The observations demonstrate the 
feasibility of Impella-2.5–implantation in patients requiring urgent hemodynamic support, even in less-experienced centers. 
However, overall 30-day mortality remained high in this patient population with major hemodynamic compromise and a high 
risk of imminent death. In this severely ill patient population, the Impella-2.5 device may not provide adequate ventricular 
unloading or systemic perfusion. Further clarification in adequately powered clinical trials is needed to determine optimal 
timing and patient selection for the Impella-2.5 and subsequent definitive therapy to improve survival in this challenging 
patient population.
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